Ge Healthcare Technologies Inc.

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents

GE HealthCare expands mammography collaboration with RadNet’s DeepHealth subsidiary to extend global access to DeepHealth’s AI-powered breast cancer screening solutions

GE HealthCare announces digital integration between bkActiv™ intraoperative ultrasound system and Medtronic Stealth AXiS™ surgical navigation system

GE HealthCare to announce first quarter 2026 results on April 29, 2026

GE HealthCare Recommends Shareholders Reject "Mini-Tender" Offer by Potemkin Limited